A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ABSORB IV
- Sponsors Abbott Vascular
- 24 Sep 2019 Planned primary completion date changed from 1 Sep 2017 to 1 Apr 2022.
- 03 Oct 2018 Planned End Date changed from 1 Apr 2024 to 1 Apr 2022.
- 25 Sep 2018 According to results published in the Lancet Journal, during enrolment for this study, it became evident from earlier studies, that BVS was associated with an excessive rate of device thrombosis compared with metallic DES and this risk typically emerged within 30 days and the study protocol was revised with change in primary endpoint (target lesion failure) time frame from 1 year to 30 days to afford earlier public disclosure of the results.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History